Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RITUXILUP: Rituximab without Oral Steroids for Lupus Nephritis
NCT01773616Phase 3Terminated
- Sponsor
- Imperial College London
- Start
- Apr 2015
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of rituximab in lupus nephritis (LN), sponsored by Imperial College London. Started Apr 2015; status: terminated.
02
Drugs
rituximab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT01773616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01773616.